首页> 外文OA文献 >Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock
【2h】

Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock

机译:在致死性失血性休克的大鼠模型中,用新型半gramicidin-TEMPO缀合物治疗可延长生存期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE: We sought to develop a therapeutic agent that would permit prolongation of survival in rats subjected to lethal hemorrhagic shock (HS), even in the absence of resuscitation with asanguinous fluids or blood. METHODS AND RESULTS: We synthesized a series of compounds that consist of the electron scavenger and superoxide dismutase mimic, 4-amino-2,2,6,6-tetramethylpiperidine- N-oxyl (4-NH 2 -TEMPO), conjugated to fragments and analogs of the membrane-active cyclopeptide antibiotic, gramicidin S. Using an in vivo assay, wherein isolated intestinal segments were loaded inside the lum en with various test compounds, we studied these compounds for their ability to prevent ileal mucosal barrier dysfunction induced by subjecting rats to profound HS for 2 hours. The most active compound in this assay, XJB-5-131, ameliorated peroxidation of the mitochondrial phospholipid, cardiolipin, in ileal mucosal samples from rats subjected to HS. XJB-5-131 also ameliorated HS-induced activation of the pro-apoptotic enzymes, caspases 3 and 7, in ileal mucosa. Intravenous treatment with XJB-5-131 (2 μmol/kg) significantly prolonged the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a minimal volume of crystalloid solution (2.8 mL/kg) and the absence of blood transfusion. CONCLUSION: These data support the view that mitochondrially targeted electron acceptors and SOD mimics are potentially valuable therapeutics for the treatment of serious acute conditions, such as HS, which are associated with marked tissue ischemia. Copyright © 2007 Lippincott Williams & Wilkins.
机译:目的:我们试图开发一种治疗剂,即使在没有用液体或血液复苏的情况下,也可以延长致死性失血性休克(HS)大鼠的生存期。方法和结果:我们合成了一系列由电子清除剂和超氧化物歧化酶模拟物4-氨基-2,2,6,6-四甲基哌啶-N-氧基(4-NH 2 -TEMPO)缀合的化合物和膜活性环肽抗生素,即短杆菌肽S的类似物。使用体内分析方法,其中将分离的肠段内腔中装载了各种测试化合物,我们研究了这些化合物预防由受试对象引起的回肠粘膜屏障功能障碍的能力。大鼠至深刻的HS 2小时。该试验中活性最高的化合物XJB-5-131改善了HS大鼠回肠粘膜样品中线粒体磷脂,心磷脂的过氧化作用。 XJB-5-131还改善了回肠粘膜中HS诱导的促凋亡酶胱天蛋白酶3和7的活化。 XJB-5-131(2μmol/ kg)的静脉治疗显着延长了遭受严重失血(33.5 mL / kg)的大鼠的存活,尽管仅施用了最小量的晶体溶液(2.8 mL / kg)而没有输血。结论:这些数据支持以下观点:线粒体靶向的电子受体和SOD模拟物对于治疗严重急性疾病(例如HS)具有潜在的有价值的疗法,这些疾病与明显的组织缺血有关。版权所有©2007 Lippincott Williams&Wilkins。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号